Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8)

Masahito Kotaka, Yoji Saito, Takeshi Kato, Hironaga Satake, Akitaka Makiyama, Yasushi Tsuji, Katsunori Shinozaki, Toshiyoshi Fujiwara, Tsunekazu Mizushima, Yasushi Harihara, Naoki Nagata, Naoto Kurihara, Masahiko Ando, Genichi Kusakawa, Takumi Sakai, Yugo Uchida, Mikihiro Takamoto, Saki Kimoto, Ichinosuke Hyodo

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the Original publication of the article, the authors found an error in the “Results” section under the heading “Abstract”. The corrected text is given below:Seventy-nine participants (placebo n = 28, 1-day ART n = 27, 3-day ART n = 24) received study drugs. The leastsquares mean FACT/GOG-Ntx-12 scores at cycle 12 from the mixed effect model for repeated measures were 28.9 with placebo, 36.3 with 1-day ART [vs. placebo: 7.3 (95% CI 1.9 to 12.8, p = 0.009)], and 32.3 with 3-day ART [vs. placebo: 3.4 (95% CI −2.1 to 9.0, p = 0.222)].

Original languageEnglish
Pages (from-to)585-586
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Volume87
Issue number4
DOIs
Publication statusPublished - Apr 2021

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correction to: A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy (Cancer Chemotherapy and Pharmacology, (2020), 86, 5, (607-618), 10.1007/s00280-020-04135-8)'. Together they form a unique fingerprint.

Cite this